Matrix Pharmaceuticals raises new funds:
This article was originally published in Clinica
Executive Summary
Matrix Pharmaceuticals has raised $67 million in a public offering. The Californian developer of site-specific injectable gels for cancer treatment has sold 3.2 million shares including the underwriters' over-allotment option at a price of $22.63 each.